RxSight faces class action lawsuit alleging securities fraud.

• RxSight faces a class action lawsuit for potential securities fraud • Lawsuit filed by Pomerantz LLP, alleging unlawful business practices • Investors who purchased shares between Feb. 22, 2025 and July 7, 2025 must act by Sep. 22, 2025 • Complaint available at www.pomerantzlaw.com • Lawsuit concerns preliminary Q2 2025 financial results reported on July 8, 2025 • RxSight's stock performance during the class period under scrutiny • Investors advised to contact Danielle Peyton for more information • Those who inquire must provide mailing address, phone number, and number of shares purchased

RxSight, Inc. (NASDAQ: RXST) is facing a class action lawsuit alleging potential securities fraud and unlawful business practices. The lawsuit, filed by Pomerantz LLP, targets investors who purchased shares between February 22, 2025, and July 7, 2025. Investors are advised to act by September 22, 2025, to request the appointment of a lead plaintiff [1][2].

The class action lawsuit concerns preliminary Q2 2025 financial results reported on July 8, 2025, which revealed significant declines in Light Delivery Device (LDD) sales, light adjustable intraocular lenses utilization, and overall revenue. RxSight's Chief Executive Officer, Ronald Kurtz, attributed these declines to "adoption challenges over the last few quarters" [1][2].

Following the release of these results, RxSight's stock price fell $4.84 per share, or 37.84%, to close at $7.95 per share on July 9, 2025 [1][2]. The lawsuit alleges that the company and its officers made false statements and concealed information about the company's financial health and business prospects [3].

Investors who believe they have suffered losses are encouraged to contact Danielle Peyton at Pomerantz LLP for more information. Those who inquire by email must include their mailing address, telephone number, and the number of shares purchased [1][2].

The complaint can be obtained at www.pomerantzlaw.com. Investors have until September 22, 2025, to request the appointment of a lead plaintiff [1][2].

References:
[1] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-rxsight-inc-of-class-action-lawsuit-and-upcoming-deadlines---rxst-302527390.html
[2] https://www.globenewswire.com/news-release/2025/08/17/3134613/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Reminds-Investors-with-Losses-on-their-Investment-in-RxSight-Inc-of-Class-Action-Lawsuit-and-Upcoming-Deadlines-RXST.html
[3] https://www.morningstar.com/news/pr-newswire/20250819ny53798/levi-korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-september-22-2025-in-rxsight-inc-lawsuit-rxst